Navigation Links
Potentia Pharmaceuticals' Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
Date:11/10/2008

AMD Patients Treated with POT-4 Demonstrate No Adverse Toxic Effects

ATLANTA, Nov. 10 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), presented Phase I data last week during the Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) Annual Meeting in Atlanta, GA. The data was from the ASaP (Assessment of Safety of Intravitreal POT-4 Therapy for Patients with Neovascular Age-Related Macular Degeneration) clinical trial for the company's leading drug candidate, POT-4, which is being developed for the treatment of AMD.

The ASaP trial is a first-in-man, multi-center, single escalating dose study. The interim results of this trial revealed no drug-related toxicity based on clinical signs, ophthalmic examinations, or laboratory results at any time point monitored in patients treated with up to 150 microgram/dose of POT- 4. Additionally, no serious adverse events and no identifiable intraocular inflammation were reported.

Preliminary results indicate that intravitreal POT-4 is safe, and the data accumulated so far support the continued investigation of POT-4 for the treatment of both dry and wet AMD with larger randomized clinical trials to further define its efficacy profile.

"These safety data strongly support the further development of POT-4 as a potential treatment for patients with AMD," said Cedric Francois, President and CEO of Potentia Pharmaceuticals. "We believe that the product has significant promise based on these early-stage findings and look forward to further testing of the compound in higher doses as we continue this trial."

About POT-4

POT-4 is a complement inhibitor, which shuts down the complement activation cascade that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factor (VEGF) in the eye.
'/>"/>

SOURCE Potentia Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Discovery of creator gene for cerebral cortex points to potential stem cell treatments
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... Calif. , April 20, 2015  Ardelyx, ... company focused on cardio-renal, gastrointestinal and metabolic diseases, ... MRCP, has joined the Company,s Board of Directors. ... and board level experience, having built and led ... development, regulatory approval and into healthcare systems globally. ...
(Date:4/20/2015)... INDIANAPOLIS , April 20, 2015  Eli Lilly ... stage data from several targeted cancer therapies, reflecting Lilly,s ... Research (AACR) Annual Meeting 2015, held April 18-22 in ... "Bringing Cancer Discoveries to Patients" is the theme of ... through Lilly,s commitment to broadening its portfolio of therapies ...
(Date:4/20/2015)... - Development of a Novel ... VOLVOX Platform - To be Presented on Tuesday, Apr ... Assembly of Antibody-drug Conjugates Using an anti-HER2 Monoclonal Antibody ... Apr 19, 1:00 PM EST Invictus Oncology ... announced that the company,s novel computational platform technology (VOLVOX) ...
(Date:4/20/2015)... BEIJING, April 20, 2015 Sinovac Biotech Ltd. ... China, today announced its unaudited financial results for the ... Fourth Quarter 2014 Financial Highlights(Compared to the ... $20.3 million, a decrease of 11.4% from $22.9 million ... the stockpiling of H5N1 pandemic influenza vaccine of $0.1 ...
Breaking Biology Technology:Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6Invictus Oncology Announces Two Posters to be Presented Describing its Platform Technology on Supramolecular Therapeutics at the American Association for Cancer Research Annual Meeting, 2015 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 2Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 3Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 4Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 5Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 6Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 7Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 8Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 9Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 10Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 11Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 12Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 13Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 14Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 15Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 16Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 17Sinovac Reports Unaudited Fourth Quarter and Full Year 2014 Financial Results 18
... ISELIN, N.J., Sept. 12 SyntheMed, Inc. ... will host a symposium,entitled "Post-Operative Adhesions in ... next week,s European Association for,Cardio- Thoracic Surgery ... be chaired by Professor Stephen Westaby of ...
... Sept. 12 Two new white papers ... free download from,Microtest ( http://www.microtestlabs.com ). The ... device manufacturers and one which is specialized,for ... associated with sterility testing and reviews different ...
... 12 Prolog Ventures, a venture capital,firm specializing ... has joined the firm as its fourth partner. ... early-stage investing, venture fund,management, and technology commercialization. ... director at Mason,Wells in Milwaukee, WI, where he ...
Cached Biology Technology:SyntheMed to Host Symposium on Adhesions in Cardiac Surgery 2Free White Papers Detail Sterility Testing Essentials for Medical Device, Pharmaceutical Manufacturers 2Dan Broderick Joins Prolog Ventures as Partner 2Dan Broderick Joins Prolog Ventures as Partner 3
(Date:3/31/2015)... March 31, 2015  Elephant Talk Communications Corp. (NYSE ... provider of Software Defined Network Architecture (ET Software DNA® ... revenue of approximately $20.4 million for the year ended ... million for the year ended December 31, 2013. ... Company had completed its multi-year transition away from its ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ... Biometrics - Global Strategic Business Report" report to their offering. ... Voice Biometrics in US$ Thousands by the following Segments: Face Biometrics, ... US, Canada , Japan , ... Middle East & Africa , ...
(Date:3/23/2015)... March 23, 2015  In the 2014 fiscal year, ... conviction losses. This figure accounts for a fraction of ... The Nilson Report, exceeds $11 billion globally. The polygraph ... a crime has occurred. Investor Mark Saint Juste ... Joe Paolella partnered to administer the test ...
Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... October 17, 2011 The Peggy Lillis Memorial ... and Senior Vice President of Optimer Pharmaceuticals, Inc. and ... Tufts University, with an achievement award to recognize his ... new treatments for Clostridium difficile infection (CDI) ...
... -- October 17, 2011-- In a paper published today in ... Mary R. Loeken, PhD, has identified the enzyme AMP kinase (AMPK) ... of neural tube defects such as spina bifida and some heart ... if women with diabetes -- either type 1 or type 2 ...
... occurs naturally in bacteria as Ralstonia eutropha ... biodegradable and is not dependent on fossil resources, this ... replace petroleum-based plastics. New research reported in BioMed Central,s ... an alternative method of producing PHB in microalgae. ...
Cached Biology News:Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection 2Peggy Lillis Foundation honors Dr. Sherwood Gorbach for career combating C. diff infection 3Joslin study finds clue to birth defects in babies of mothers with diabetes 2
... is portable, easy-to-use and makes identifying your samples ... Easy to use Labels withstand extreme ... sizes Time/Date stamp Laboratory ... Serialization feature makes you more efficient ...
Each 72-well MiniTray is low profile, with lid. Conical well shape, 10 l....
...
...
Biology Products: